| Literature DB >> 35546818 |
Sahar Badragheh1, Mohsen Zeeb2, Mohamad Reza Talei Bavil Olyai2.
Abstract
Herein, silica-coated iron oxide nanoparticles modified with imidazolium-based polymeric ionic liquid (Fe3O4@SiO2@PIL) were fabricated as a sustainable sorbent for magnetic solid-phase extraction (MSPE) and simultaneous determination of trace antidiabetic drugs in human plasma by high-performance liquid chromatography-ultraviolet detection (HPLC-UV). The Fe3O4 core was functionalized by silica (SiO2) and vinyl layers where the ionic liquid 1-vinyl-3-octylimidazolium bromide (VOIM-Br) was attached through a free radical copolymerization process. In order to achieve hydrophobic magnetic nanoparticles and increase the merits of the sorbent, Br- anions were synthetically replaced with PF6 -. The properties and morphology of the sorbent were characterized by various techniques and all the results illustrated the prosperous synthesis of Fe3O4@SiO2@PIL. A comprehensive study was carried out to investigate and optimize various parameters affecting the extraction efficiency. The limit of detection (LOD, S/N = 3) for empagliflozin, metformin and canagliflozin was 1.3, 6.0 and 0.8 ng mL-1, respectively. Linearity (0.997 ≥ r 2 ≥ 0.993) and linear concentration ranges of 5.0-1200.0, 20.0-1800.0 and 5.0-1000.0 ng mL-1 were obtained for empagliflozin, metformin and canagliflozin, respectively. Intra-assay (3.8-7.5%, n = 9) and inter-assay (3.2-8.5%, n = 12) precisions as well as accuracies (≤9.1%) displayed good efficiency of the method. Finally, the method was applied for the quantitation of antidiabetic drugs in human plasma after oral administration and main pharmacokinetic data including T max (h), C max (ng mL-1), AUC0-24 (ng h mL-1), AUC0-∞ (ng h mL-1), and T 1/2 (h) were evaluated. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35546818 PMCID: PMC9085437 DOI: 10.1039/c8ra02109k
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chemical structures of EMPA, MET, CANA.
Fig. 2Schematic diagram of the preparation Fe3O4@SiO2@PIL MNPs and its application as MSPE sorbent for extraction and preconcentration of target drugs.
Fig. 3(A) The transmission electron microscopy image of Fe3O4@SiO2@PIL-PF6; (B) The FT-IR spectra of Fe3O4 (a), Fe3O4@SiO2 (b), Fe3O4@SiO2@VTES (c). Fe3O4@SiO2@PIL-Br (d) Fe3O4@SiO2@PIL-PF6 (e); (C) XRD pattern of the Fe3O4 (a) and Fe3O4@SiO2@PIL-PF6 (b) nanoparticles; (D) Magnetic hysteresis loops of Fe3O4 (a) and Fe3O4@SiO2@PIL-PF6 (b).
Fig. 4The field emission scanning electron microscopy images of Fe3O4 (a), Fe3O4@SiO2 (b) and Fe3O4@SiO2@PIL-PF6 (c).
Fig. 5(A) Effect of Fe3O4@SiO2@PIL-PF6 MNPs amount; experimental conditions: concentration of each drug 250.0 ng mL−1; pH 4.0; extraction time 4 min; desorption solvent ACN; desorption time 2 min. (B) Effect of sample pH; experimental conditions: concentration of each drug 250.0 ng mL−1; sorbent amount 10.0 mg; extraction time 4 min; desorption solvent ACN; desorption time 2 min. (C) Effect of extraction time; experimental conditions: concentration of each drug 250.0 ng mL−1; sorbent amount 10.0 mg; pH 4.0; desorption solvent ACN; desorption time 2 min. (D) Effect of ionic strength; experimental conditions: concentration of each drug 250.0 ng mL−1; sorbent amount 10.0 mg; pH 4.0; extraction time 4 min; desorption solvent ACN; desorption time 2 min.
Analytical characteristics of the proposed MSPE-HPLC-UVa
| Analyte | LDR (ng mL−1) | Linear equation |
| LOD (ng mL−1) | LOQ (ng mL−1) | EF | ER% ( |
|---|---|---|---|---|---|---|---|
| EMPA | 5.0–1200.0 |
| 0.996 | 1.3 | 5.0 | 18.4 | 92.0 |
| MET | 20.0–1800.0 |
| 0.993 | 6.0 | 20.0 | 17.3 | 86.5 |
| CANA | 5.0–1000.0 |
| 0.997 | 0.8 | 5.0 | 18.5 | 92.5 |
LDR: Linear dynamic range; r2: correlation coefficient; LOD: limit of detection; LOQ: limit of quantification; EF: enrichment factor; ER: extraction recovery (250.0 ng mL−1 of each drug was used).
Fig. 6The chromatograms of EMPA, MET and CANA in human plasma; (a) blank; spiked plasma at (b) 100.0 ng mL−1, (c) 250.0 ng mL−1 and (d) 400.0 ng mL−1 concentration levels of each drug.
Intra-day and inter-day precision and accuracy for quantification of EMPA, MET and CANA in human plasmaa
| Drug | Concentration (ng mL−1) | Intra-day, | Inter-day, | ||||
|---|---|---|---|---|---|---|---|
| Found value ± SD (ng mL−1) | RSD (%) | Accuracy (%) | Found value ± SD (ng mL−1) | RSD (%) | Accuracy (%) | ||
| EMPA | 25.0 | 26.8 ± 1.3 | 4.8 | 7.2 | 22.9 ± 1.2 | 5.2 | −8.4 |
| 500.0 | 529.0 ± 21.7 | 4.1 | 5.8 | 545.5 ± 27.3 | 5.0 | 9.1 | |
| 1000.0 | 1036.0 ± 39.4 | 3.8 | 3.6 | 958.0 ± 42.1 | 4.4 | −4.2 | |
| MET | 25.0 | 26.6 ± 1.5 | 5.6 | 6.4 | 26.8 ± 1.7 | 6.3 | 7.2 |
| 500.0 | 530.0 ± 38.2 | 7.2 | 6.0 | 543.1 ± 36.9 | 6.8 | 8.6 | |
| 1000.0 | 1044.0 ± 42.8 | 4.1 | 4.4 | 1050.0 ± 33.6 | 3.2 | 5.0 | |
| CANA | 25.0 | 26.5 ± 1.3 | 4.9 | 6.0 | 27.0 ± 2.3 | 8.5 | 8.0 |
| 500.0 | 520.5 ± 39.0 | 7.5 | 4.1 | 526.5 ± 41.1 | 7.8 | 5.3 | |
| 1000.0 | 1039.0 ± 41.6 | 4.0 | 3.9 | 1066.0 ± 42.9 | 4.0 | 6.6 | |
RSD (%) = 100 × SD/mean; accuracy (%) = (mean concentration found − known concentration)/(known concentration); intraday (n = 12) = triplicate samples within a series of six measurements on different days.
Pharmacokinetic parameters of EMPA, MET and CANA after oral administration of a fixed-dose combination Invokamet tablet (50 mg CANA/500 mg MET) and a single dose of Jardiance tablet (EMPA 25 mg)a
| Pharmacokinetic parameters | Mean ± SD | ||
|---|---|---|---|
| CANA | MET | EMPA | |
|
| 3.2 ± 0.3 | 4.1 ± 0.5 | 2.9 ± 0.3 |
|
| 390.4 ± 50.2 | 859.7 ± 91.2 | 215.6 ± 44.1 |
| AUC0–24 (ng h mL−1) | 3862.8 ± 426.9 | 6627.1 ± 699.3 | 1398.7 ± 122.5 |
| AUC0–∞ (ng h mL−1) | 3973.6 ± 508.5 | 7022.8 ± 703.6 | 1426.0 ± 150.8 |
|
| 12.1 ± 1.4 | 6.3 ± 0.8 | 7.2 ± 1.1 |
T max: Time required for reaching maximum plasma concentration, Cmax: maximum plasma concentration, AUC0–24: area under curve, AUC0–∞: area under curve at infinite time, T1/2 (h): time required for reaching to half concentration.
Comparison of the presented approach with other methods for determination of different antidiabetic drugs in human plasma
| Sorbent/extraction method | Drug | LOD (ng mL−1) | DLR (ng mL−1) |
| RSD (%) | Separation/detection system | Ref. |
|---|---|---|---|---|---|---|---|
| Sequential HF-LPME | MET | 1 | 5–2500 | 0.999 | <8.4% | HPLC-UV |
|
| IP-VALLLME | MET | 1400 | 20 000–2000000 | 0.9988 | <10.8 | HPLC-UV |
|
| IPSPE | MET | 3 | 50–2000 | ≥0.997 | <9% | HPLC-UV |
|
| SPE cartridge | MET | 1480 | — | ≥0.9992 | <13.4 | HPLC-ESI-MSn |
|
| SPE | CANA | — | 10.3–6019 | ≥0.99 | — | LC-MS/MS |
|
| LLE | EMPA | — | — | 0.9997 | <6.99 | LC-MS/MS |
|
| MSPE | EMPA | 1.3 | 5.0–1200.0 | 0.996 | ≤5.2 | HPLC-UV | This work |
| MET | 6.0 | 20.0–1800.0 | 0.993 | ≤6.8 | |||
| CANA | 0.8 | 5.0–1000.0 | 0.997 | ≤8.5 |
Sequential hollow-fiber liquid phase microextraction.
Ion-pair vortex assisted liquid–liquid microextraction.
Ion pair solid phase extraction.
Solid phase extraction.
High performance liquid chromatography-electrospray ionization multi-stage mass spectrometry.
Liquid–liquid extraction.